All In MedTech

Device Trial Radar · NCT05055297

SELUTION4BTK Trial

SELUTION SLR™ 014 BTK: A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

May 19, 2022

Primary completion

Jun 1, 2027

Study completion Jul 30, 2032

Sponsor

Lead sponsor
M.A. Med Alliance S.A.Not on our public-company list
Sponsor type
Industry
Collaborators
NAMSA; Cordis US Corp.
First posted
Sep 24, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

Conditions

  • Peripheral Arterial Disease
  • Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities

Interventions

  • SELUTION SLR™ DEB 014Device

    a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

  • Plain (Uncoated) Balloon Angioplasty (PTA)Device

    a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy EndpointTime frame: 6 months
  2. Primary Safety EndpointTime frame: 30 days

Locations

48 sites in 10 countries. Site status is shown where the registry gives one.

  • Chandler Regional Medical Center

    Chandler, Arizona · Recruiting

  • St. Bernards Medical Center

    Jonesboro, Arkansas · Recruiting

  • Arkansas Heart Hospital

    Little Rock, Arkansas · Terminated

45 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.